New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
07:33 EDTATRSAntares Pharma'a Otrexup NDA accepted by FDA
Antares Pharma announced that the New Drug Application for Otrexup, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the FDA indicating that the application is sufficiently complete to permit a substantive review. Otrexup is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis, poly-articular-course juvenile RA and psoriasis. The FDA has assigned a target date of October 14, ten months from the official NDA filing, to complete its review of the NDA.
News For ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
16:21 EDTATRSAntares Pharma gets written notice of termination of agreement from Pfizer
On December 12, 2011, Antares Pharma (ATRS) entered into a licensing agreement with Pfizer (PFE) Consumer Healthcare for one of our drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. On October 5, the Company received a written notice of termination of the Agreement from Pfizer. Pfizer informed the Company that the product Pfizer was developing failed to meet pre-specified endpoints in a clinical study. Accordingly, the Agreement will terminate on November 5.
September 28, 2015
07:12 EDTATRSAntares announces publication of QuickShot Testosterone data in health journal
Subscribe for More Information
September 25, 2015
08:37 EDTATRSAntares Pharma could benefit from drug pricing controversy, says Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use